benserazide


Also found in: Wikipedia.

benserazide

 [ben-ser´ah-zīd]
an inhibitor of the decarboxylation of peripheral levodopa to dopamine, having actions similar to those of carbidopa. When given with levodopa, benserazide produces higher brain concentrations of dopamine with lower doses of levodopa, thus lessening the side effects seen with higher doses. It is used orally, in conjunction with levodopa, as an antiparkinsonian agent.

ben·ser·a·zide

(ben-ser'ă-zīd),
An l-aromatic amino acid decarboxylase (dopa decarboxylase) inhibitor resembling carbidopa in action; given in combination with levodopa as an antiparkinsonian regimen. The benserazide prevents peripheral destruction of levodopa and thus reduces cardiovascular side effects of treatment.

benserazide

/ben·ser·a·zide/ (ben-ser´ah-zīd) an inhibitor of decarboxylation of levodopa in extracerebral tissues, used in combination with levodopa as an antiparkinsonian agent.

benserazide

[ben-ser′ah-zīd]
an inhibitor of the decarboxylation of peripheral levodopa to dopamine, having actions similar to those of carbidopa. When given with levodopa, benserazide produces higher brain concentrations of dopamine with lower doses of levodopa, thus lessening the side effects seen with higher doses. It is used orally in conjunction with levodopa as an antiparkinsonian agent.

benserazide

A dopamine precursor drug given in conjunction with LEVODOPA in the treatment of PARKINSON'S DISEASE to prevent the breakdown of levodopa in the body. A brand name is Madopar.
References in periodicals archive ?
In a paper (containing 90 scientific references) published in Clinical Pharmacology, Hinz, Alvin Stein, and Ted Cole note that the only indication for carbidopa and benserazide is the management of L-dopa-induced nausea.
Contract awarded for The purpose of this call is acquiring 100,000 carbamazepine 200 mg tablets, 20,000 tablets of levodopa / benserazide 200/50 mg.
It is often given with a peripheral decarboxylase inhibitor, eg, carbidopa or benserazide, to reduce the breakdown of L-dopa outside of the brain.
In rats, a combination of levodopa, benserazide, and disulfiram injected intraperitoneally increases striatal contents of DOPAL to about 2 ng/mg protein (about 13 pmol/mg), without a semichronic effect on striatal dopamine contents after repeated injections (10).
59) Because levodopa is rapidly metabolized in the systemic circulation by dopa-decarboxylase before it crosses the blood-brain barrier, levodopa is usually administered as combination therapy with a DDI, such as carbidopa or benserazide, to reduce peripheral conversion and increase availability of levodopa in the brain.
Medical and Surgical Treatment for Parkinson's Disease Drug Therapy Benefit and Use Levodopa with carbidopa Used as first-line treatment for Sinemet CR (controlled release) many patients; improvement in Standard Sinemet (immediate mobility and activities of daily release) * living and, in some cases, mood; Levodopa with benserazide fewer side effects with con- (unavailable in USA) trolled-release preparations; Prolopa, Madopar frequently used in combination with COMT inhibitor and/or dopamine agonist.
The "Benserazide hydrochloride (CAS 14919-77-8) Market Research Report 2011" presents an overview of the Benserazide hydrochloride market globally and regionally by contemplating and analyzing its parameters.
is required levodopa / benserazide tablets 200/50 mg.
Carbidopa, available in the United States, and benserazide, available in Great Britain, are dopa-decarboxylase inhibitors and prevent the peripheral conversion of levodopa to dopamine.
Microdialysis was performed intravenously and subcutaneously in nine healthy subjects given 100 mg of L-dopa with 25 mg of benserazide.
The sales of levodopa products containing carbidopa or benserazide was USD 592 million (IMS MIDAS).